ALTEOGEN Inc.
Financials
Valuation Metrics
ALTEOGEN Inc.'s Market Cap is ₩18.6T. At end of 2025 it was ₩24.1T. Ranked #41 of 2,436 in KR market (top 2%), #1 of 1,649 on KOSDAQ (top 0.1%), #3 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 1%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 18.59T KRW | KR#41/2,436 Sec#3/234 |
| Revenue | 203.76B KRW | KR#1,006/2,436 Sec#57/234 |
| Net Income | 133.48B KRW | KR#180/2,436 Sec#10/234 |
| Total Assets | 729.47B KRW | KR#569/2,436 Sec#33/234 |
| Net Assets | 512.86B KRW | KR#482/2,436 Sec#29/234 |
| Employees | 154 | KR#1,301/2,436 Sec#106/234 |
| Value | ||
| P/E | 139.31x | KR#1,458/2,436 Sec#97/234 |
| P/B | 36.26x | KR#2,399/2,436 Sec#226/234 |
| P/S | 91.26x | KR#2,387/2,436 Sec#209/234 |
| EV/EBITDA | 217.87x | KR#1,527/2,436 Sec#107/234 |
| FCF Yield | 0.54% | KR#1,175/2,436 Sec#87/234 |
| Profitability | ||
| ROE | 26.03% | KR#66/2,436 Sec#4/234 |
| ROA | 18.30% | KR#40/2,436 Sec#5/234 |
| Op. Margin | 41.81% | KR#22/2,436 Sec#5/234 |
| Revenue Growth | -14.45% | KR#1,976/2,436 Sec#180/234 |
| Earnings Growth | -14.08% | KR#1,008/2,436 Sec#66/234 |
| Financial Health | ||
| Debt Ratio | 142.24% | KR#1,077/2,436 Sec#123/234 |
| Total Debt | 6.65B KRW | KR#1,732/2,436 Sec#162/234 |
| FCF | 101.12B KRW | KR#192/2,436 Sec#11/234 |
| Cash | 42.28B KRW | KR#836/2,436 Sec#54/234 |
| Current Ratio | 2.41x | KR#779/2,436 Sec#95/234 |
| Net Debt/EBITDA | -0.42x | KR#599/2,436 Sec#36/234 |
| Dividend | ||
| Div. Yield | 0.12% | KR#1,370/2,436 Sec#87/234 |
| Performance | ||
| 1Y Return | -19.68% | KR#1,253/2,436 Sec#103/234 |
| 1M Return | 1.61% | KR#722/2,436 Sec#62/234 |
| From 52W High | -39.02% | KR#717/2,436 Sec#51/234 |
| 1Y MDD | -52.06% | KR#1,021/2,436 Sec#83/234 |
| Trading | ||
| Volume | 571,972 shares | KR#246/2,436 Sec#22/234 |
| Foreign Own. | 14.75% | KR#320/2,436 Sec#21/234 |
| Per Share | ||
| EPS | 2,415 KRW | KR#342/2,436 Sec#24/234 |
| BPS | 9,344 KRW | KR#990/2,436 Sec#69/234 |
Company Info
Established in 2008, Alteogen is a biopharmaceutical research, development, and sales company listed on the KOSDAQ market in 2014. The company holds and researches platform technologies including Hybrozyme™ for converting intravenous to subcutaneous injections, NexP™ for sustained-release biopharmaceuticals, and NexMab™ for next-generation antibody-drug conjugates. It aims to generate technology transfer, service, sales, and royalty revenue through licensing agreements with global multinational pharmaceutical companies. Alteogen is headquartered in Yuseong-gu, Daejeon Metropolitan City.